<html><head></head><body><div id="history-main">
			
			<div class="d_block_inner">
				<div id="actual_explanation" style="display:none;"></div>
				<div id="global-ranks" class="stat-pane">
					<div class="explanation-topper">
						<div class="left-topper">
							<h1 class="post-title">Proton Pump Inhibitors</h1>
							<h4 class="sidebar-header tax_links"><a href="https://mrcemsuccess.com/qc/5/">Pharmacology</a> / 
	<a href="https://mrcemsuccess.com/qc/gastrointestinal-5/">Gastrointestinal</a></h4>
						</div>
						<div class="right-topper" id="right-info">
							<h4 class="sidebar-header" id="page-numbers">Last Updated: 26th March 2019</h4>
							<button class="simplefavorite-button" data-postid="102144" data-siteid="1" data-groupid="1" data-favoritecount="448" style=""><i class="far fa-bookmark"> </i></button>						</div>
					</div>					<div id="ex-content" class="explanation-container"><h4>Mechanism of Action</h4>
<p>Proton pump inhibitors act by directly inhibiting the H<sup>+</sup>/K<sup>+</sup> ATPase (proton) pump on gastric parietal cell luminal membranes and thus inhibiting acid secretion.</p>
<h4>Indications</h4>
<p>Proton pump inhibitors may be indicated for:</p>
<ul>
<li>treatment of gastric and duodenal ulcers</li>
<li>eradication of Helicobacter pylori in combination with antibacterials</li>
<li>treatment of dyspepsia and GORD</li>
<li>post-endoscopic treatment of severe peptic ulcer bleeding (an intravenous high dose PPI reduces risk of rebleeding and the need for surgery)</li>
<li>treatment and prevention of NSAID-associated ulcers</li>
<li>cystic fibrosis (reduces degradation of pancreatic enzyme supplements)</li>
<li>Zollinger-Ellison syndrome (controls excessive gastric acid secretion)</li>
</ul>
<h4>Cautions</h4>
<p>Proton pump inhibitors:</p>
<ul>
<li>can increase the risk of fractures (particularly when used at high doses for over a year in the elderly or used in those at risk of osteoporosis)</li>
<li>may increase the risk of gastrointestinal infections (including Clostridium difficile infection)</li>
<li>may mask the symptoms of gastric cancer (in patients with 'alarm features', gastric malignancy should be ruled out before starting treatment)</li>
<li>can cause false negative H. pylori test results (and should be stopped at least 2 weeks before testing)</li>
</ul>
<h4>Side Effects</h4>
<p>Common side effects (usually mild and reversible) include:</p>
<ul>
<li>abdominal pain</li>
<li>constipation</li>
<li>diarrhoea</li>
<li>flatulence</li>
<li>headache</li>
<li>nausea</li>
<li>vomiting</li>
<li>dizziness</li>
<li>skin rashes</li>
</ul>
<p>Possible adverse effects of long-term PPI treatment:</p>
<ul>
<li>Hypomagnesaemia (measurement of serum magnesium concentrations should be considered before and during prolonged treatment with a PPI, especially when used with other drugs that cause hypomagnesaemia or with digoxin)</li>
<li>Rebound acid hypersecretion and protracted dyspepsia after stopping prolonged treatment</li>
<li>Interstitial nephritis</li>
<li>Vitamin B12 deficiency</li>
</ul>
<h4>Administration</h4>
<p>Omeprazole:</p>
<ul>
<li>H. pylori eradication regimen dose: 20 mg od</li>
<li>Healing peptic ulcer: 20 mg od (40 mg od may be used in severe or recurrent cases)</li>
<li>Healing NSAID-associated ulcer: 20 mg od</li>
<li>Prophylaxis for NSAID-associated ulcer: 20 mg od</li>
<li>Major peptic ulcer bleeding (following endoscopic treatment): Initially 80&nbsp;mg, to be given over 40â€“60 minutes, then (by continuous intravenous infusion) 8&nbsp;mg/hour for 72 hours, subsequent dose then changed to oral therapy</li>
</ul>
</div>
				
						
				
				</div>	
				
			
	
			</div>
			<div id="scrollup" class="active textbook"><i class="fa fa-chevron-up"></i></div>
		</div></body></html>